TENX logo

TENX Tenax Therapeutics, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$1.25
-0.14 (-10.07%)

Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to mana…

Market Cap: $33.16Mwww.tenaxthera.com

Price

No data yet.

Social Signal Score

26
5d
—
30d
25
5 mentions
—
60d
25
5 mentions
—
90d
26
6 mentions
—
news: 6

Analyst Ratings

9 analysts
Buyconsensus
Strong Buy 0Buy 5Hold 4Sell 0Strong Sell 0
Avg price target$4.4+252.0%
Low $4Median $4High $5
Current Consensus

Revenue

$0.00-100.00%
$0.00$3.5K$7.1K$10.6K
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-1.37
$-1.39–$-1.36
3 analysts
FY2026
$-1.39
$-1.51–$-1.18
7 analysts
FY2027
$-1.31
$-1.53–$-1.07
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Christopher T. Giordano
Sector
Healthcare
Industry
Biotechnology
Employees
15
Beta
0.97
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-3.41
www.tenaxthera.com